Experimental Study on the Growth of HepG2 cell line by Methylyprednisolone in Vitro

Abstract

Abstract: 【Abstrct】:Objective To investigate the efficacy and the possible mechanism of HepG2 cell line induced by methylyprednisolone (MP) in vitro.Methods The proliferation of HepG2 cells treated with MP was determined by MTT assay. Flow cytometry was used to detect cell cycle and apoptosis induced by MP. HepG2 cells were randomly divided into 6 groups: the control group, the MP group I (MP 10u/l), group II (MP20ug/l), group III (MP50ug/l), group IV (MP500ug/l), group V (MP5000ug/l). The expression of VEGF mRNA of HepG2 cells was detected by fluorescent quantitation ploymerase chain reaction (FQ-PCR). The VEGF concentration of supernate of HepG2 cells was measured by ELISA. Results MP enhanced the proliferation of HepG2 cells at the concentration of 50-5000ug/l in vitro. The expression of VEGF mRNA was promoted significantly by MP at the concentration of 500-5000ug/l. The expression of VEGF mRNA in the control group, the MP group I , group II, group III, group IV, group V was (4.761±0.624)、(4.679±0.875)、（5.554±0.541）、（5.710±1.22）、（7.293±0.409）、(8.231±0.216）(P＜0.01). The supernate concentration of VEGF was promoted significantly by MP at the concentration of 500-5000ug/l (P＜0.01).Conclusion High dose of methylyprednisolone can enhance the growth of hepatocellular carcinoma cell lines HepG2 in vitro and up-regulate the transcription and translation of VEGF mRNA.

Key words: Methylyprednisolone, Hepatocellular carcinoma, Vascular endothelial growth factor

摘要： 目的探讨甲基强的松龙（MP）对肝癌HepG2细胞生长的影响及相关机制。方法 MTT法测定不同浓度MP对HepG2细胞增殖的影响；细胞分为6个处理组：对照组、MPⅠ组（10 ug/l）、MPⅡ组（20 ug/l）、MPIII组（50 ug/l）、MPIV组（500 ug/l）、MPV组（5000 ug/l）；流式细胞仪测定MP对HepG2细胞周期和凋亡情况的作用；荧光定量PCR法测定MP对HepG2细胞VEGF mRNA表达的影响；ELISA法测定细胞培养上清液VEGF浓度。结果 50-5000ug/l的MP作用72h，能促进HepG2细胞的增殖；MP对HepG2细胞周期和凋亡无影响；不同浓度的MP作用72h后，HepG2细胞VEGF mRNA的转录和蛋白表达有显著性差异（P＜0.01），MP在500ug/l和5000ug/l浓度时， VEGF mRNA表达量分别为（7.293±0.409）拷贝数/ul对数值和（8.231±0.216）拷贝数/ul对数值，高于对照组（4.761±0.624）拷贝数/ul对数值，结果有显著性差异（P＜0.01），VEGF浓度分别为（11.153±1.552）ug/l和（11.456±1.517）ug/l，高于对照组（7.362±0.510）ug/l，结果有显著性差异（P＜0.01）；。结论高浓度的MP在体外能促进肝癌HepG2细胞增殖，上调其VEGF mRNA的转录和翻译。

关键词: 甲基强的松龙, 肝细胞癌, 血管内皮生长因子

CLC Number:

R735.7

曾纪晓夏慧敏朱德力何晓顺. 甲基强的松龙对体外肝癌HepG2细胞生长的影响[J]. 岭南现代临床外科, 2012, 12(01): 16-19.

References

[1]Gaumann A, Schlitt HJ, Geissler EK.Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin[J].Transpl Int,2008,21(3):207-2017
[2]2. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol. 2001 ,34(1):84-91
[3]3. Vivarelli M, Bellusci R, Cucchetti A, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation.2002,74(12):1746-1751
[4]4. Regalia E, Sansalone C, Mazzaferro V, et al. Pattern of recurrence of hepatocellular carcinoma after liver transplantation: Milan multicenter experience. Transplant Proc.1994,26(6):3579-3580
[5]5. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer.2008,8(8):579-591
[6]Kaseb AO, Hassan MM, Lin E, Xiao L,et al.Cancer[J].V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials,2010,117(11):2478-2488
[7]Zhu AX, Sahani DV, Duda DG, di Tomaso E, et al.Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study[J].J Clin Oncol,2009,27(18):3027-3035
[8]8. Finn RS, Zhu AX.Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther.2009,9(4):503-509
[9]Gaumann A, Schlitt HJ, Geissler EK.Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin[J].Transpl Int,2008,21(3):207-2017
[10]Haagsma EB, Hagens VE, Schaapveld M, et al.Increased cancer risk after liver transplantation: a population-based study[J].J Hepatol,2001,34(1):84-91
[11]Vivarelli M, Bellusci R, Cucchetti A, et al.Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression[J].Transplantation,2002,74(12):1746-1751
[12]Vivarelli M, Bellusci R, Cucchetti A, et al.Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression[J].Transplantation,2002,74(12):1746-1751
[13]Ellis LM, Hicklin DJ.VEGF-targeted therapy: mechanisms of anti-tumour activity[J].Nat Rev Cancer,2008,8(8):579-591
[14]Kaseb AO, Hassan MM, Lin E, Xiao L,et al.CancerV-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials[J].,2010,117(11):2478-2488
[15]Zhu AX, Sahani DV, Duda DG, di Tomaso E, et al.Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study[J].J Clin Oncol,2009,27(18):3027-3035
[16]Finn RS, Zhu AX.Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab[J].Expert Rev Anticancer Ther,2009,9(4):503-509